MX2021010228A - Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. - Google Patents
Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.Info
- Publication number
- MX2021010228A MX2021010228A MX2021010228A MX2021010228A MX2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A
- Authority
- MX
- Mexico
- Prior art keywords
- skin cancer
- patient
- inhibitor
- effective amount
- therapeutically effective
- Prior art date
Links
- 208000000453 Skin Neoplasms Diseases 0.000 title abstract 7
- 201000000849 skin cancer Diseases 0.000 title abstract 7
- 239000012270 PD-1 inhibitor Substances 0.000 title abstract 5
- 239000012668 PD-1-inhibitor Substances 0.000 title abstract 5
- 229940121655 pd-1 inhibitor Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 238000001356 surgical procedure Methods 0.000 abstract 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 2
- 238000009099 neoadjuvant therapy Methods 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 206010061819 Disease recurrence Diseases 0.000 abstract 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 abstract 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 abstract 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Abstract
La descripción se refiere a métodos para tratar o inhibir el crecimiento de un tumor en un paciente con cáncer de piel, en donde los métodos incluyen administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de muerte programada-1 (PD-1) (por ejemplo, un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a PD-1, PD-L1 y/o PD-L2). En determinadas modalidades, el método incluye administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento adyuvante después de que el paciente haya completado la cirugía y, opcionalmente, la radioterapia para cáncer de piel, tal como CSCC, y tenga un alto riesgo de recurrencia de la enfermedad. En determinadas modalidades, el método incluye administrar al paciente con cáncer de piel una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento neoadyuvante antes de la cirugía planificada para cáncer de piel. En determinadas modalidades, el método incluye administrar a un paciente con cáncer de piel una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento neoadyuvante antes de la cirugía planificada para el cáncer de piel y posteriormente administrar al paciente un inhibidor de PD-1 como terapia adyuvante después de dicha cirugía.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/020018 WO2020176699A1 (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010228A true MX2021010228A (es) | 2021-10-26 |
Family
ID=70057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010228A MX2021010228A (es) | 2019-02-28 | 2020-02-27 | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (es) |
| EP (1) | EP3930848A1 (es) |
| JP (1) | JP2022521800A (es) |
| KR (1) | KR20210134690A (es) |
| CN (1) | CN113490529A (es) |
| AU (1) | AU2020228296A1 (es) |
| CA (1) | CA3137361A1 (es) |
| IL (1) | IL285050A (es) |
| MA (1) | MA55084A (es) |
| MX (1) | MX2021010228A (es) |
| SG (1) | SG11202108089SA (es) |
| WO (1) | WO2020176699A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| CA3170208A1 (en) * | 2021-02-11 | 2022-08-18 | Elizabeth Miller | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
| RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
| EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| MX2011002252A (es) | 2008-08-25 | 2011-06-24 | Amplimmune Inc | Composiciones de antagonistas del pd-1 y metodos de uso. |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
| CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN107001463B (zh) | 2014-08-05 | 2020-01-17 | 中美冠科生物技术（太仓）有限公司 | 抗pd-l1抗体 |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| MX2018007423A (es) * | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| JP2019510832A (ja) | 2016-04-07 | 2019-04-18 | ケモセントリクス，インコーポレーテッド | Ｐｄ−１阻害剤又はｐｄ−ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| KR20240011262A (ko) * | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CA3067909A1 (en) * | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/en unknown
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/en active Pending
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko unknown
- 2020-02-27 CA CA3137361A patent/CA3137361A1/en active Pending
- 2020-02-27 AU AU2020228296A patent/AU2020228296A1/en active Pending
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285050A (en) | 2021-09-30 |
| US20220259313A1 (en) | 2022-08-18 |
| JP2022521800A (ja) | 2022-04-12 |
| MA55084A (fr) | 2022-01-05 |
| CA3137361A1 (en) | 2020-09-03 |
| AU2020228296A1 (en) | 2021-10-14 |
| WO2020176699A1 (en) | 2020-09-03 |
| EP3930848A1 (en) | 2022-01-05 |
| CN113490529A (zh) | 2021-10-08 |
| KR20210134690A (ko) | 2021-11-10 |
| SG11202108089SA (en) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
| Mahmood et al. | Radiation-induced erectile dysfunction: Recent advances and future directions | |
| MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| JP2019519499A5 (es) | ||
| JP2018502120A5 (es) | ||
| Guibert et al. | Brachytherapy in lip carcinoma: long-term results | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| MX2021010228A (es) | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| WO2020092792A3 (en) | Method of enhancing immune-based therapy | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| Annede et al. | Radiobiology: Foundation and new insights in modeling brachytherapy effects | |
| Stone et al. | Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? | |
| MX2021005266A (es) | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. | |
| PH12019502574A1 (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2022014734A (es) | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. | |
| MX2021014103A (es) | Compuestos de briostatina para mejorar la inmunoterapia. | |
| MX2021012130A (es) | Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad. | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer |